![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H20ClN5O3 |
Molar mass | 377.83 g·mol−1 |
3D model ( JSmol) | |
| |
|
Dasolampanel ( INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/ Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. [1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, [2] [3] but ultimately neither drug was ever marketed.
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C17H20ClN5O3 |
Molar mass | 377.83 g·mol−1 |
3D model ( JSmol) | |
| |
|
Dasolampanel ( INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/ Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. [1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, [2] [3] but ultimately neither drug was ever marketed.